CXI Advisors’s AbbVie ABBV Stock Holding History

CXI Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$5K	Buy	+58	New	+$4.82K	0.01%	157

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

CXI Advisors's ABBV Position: Q4 2019 in Review

CXI Advisors opened a new position in AbbVie (ABBV) in Q4 2019: 58 shares worth $5K. The stake represents 0.01% of the portfolio and ranks #157 among its holdings.

2,244 funds tracked by Wall St. Rank hold ABBV as of Q4 2019.

CXI Advisors held 58 shares of AbbVie worth $5K as of Q4 2019.
AbbVie was a new CXI Advisors position in Q4 2019.
AbbVie made up 0.01% of CXI Advisors's portfolio in Q4 2019, its #157 holding.
2,244 funds tracked by Wall St. Rank held AbbVie as of Q4 2019.

Based on CXI Advisors's 13F filing for Q4 2019, filed 27 Jan 2020.